Podcasts about PDQ

Time to Get Up with a rousing clap of Thunder - OKC and their MVP SGA are headed PDQ to the WCF! Are they the team to beat for the LOB? We'll see… Because the Knicks and Pacers will have a say in that! A rugged rematch of this roiling rivalry is on the way, we'll tell you who has the decided edge! Plus - oh it's a sneaky huge week in the NFL - we'll tell you why the sport may never be the same again if the owners get it right! Learn more about your ad choices. Visit podcastchoices.com/adchoices

We've got a full show lined up with guests and great info you won't want to miss:

  It's a quad crew this week as Jason starts his pod break. We open up the episode talking about something you would never do again in your life. Florida Man takes us to Miami for a chance at the Big Board. We wrap up the first round of the Chicken Tender Bracket with #4 Popeyes vs #13 PDQ and #5 Guthrie's vs. #12 Arby's.    Kevin has his weekly Dad Tip and Jason gives us the first Would You Rather of the new season. Jose is live with WWFU and we wrap up the episode with some Rapid Fire. Special thanks to Naomi, Blair and Henderbeard for the voice nuggets. Enjoy the chaos! Cheers!        5:50-6:30 Crushing Chobani  9:20-9:50 You Have What? 10:30-11:21 Make A Kevin 43:00-43:27 Making Up For Something  1:10:00-1:10:33 Support Your Kids 1:16:50-1:17:20 Crunchy or Soft?     CuptoCupLife.com  

Todd recaps how Josh Fernandez of PDQ won the Foundation with only waiver claims due to injuries even though he failed to draft Barkley, Henry, Chase, Allen or Jackson. The Todd Wright Fantasy Football Podcast is presented by Hooters! Click […] The post Jimmy McGinty Has A New Home In Westchase appeared first on JoeBucsFan.com.

In this episode, we turn the tables and interview Andrew Pla. We explore Andrew's back story, find out how he got started in IT, and discover where his love of PowerShell comes from. We also discuss his journey from community member to advocate to PowerShell MVP. Get to know Andrew Pla! Guest Bio and links: Andrew Pla is the host of the PowerShell Podcast, Microsoft Powershell MVP, and Community Manager at PDQ. Andrew has an extensive IT background and expertise in PowerShell. He loves interacting with the community, mentoring, and spreading the good word about PowerShell. Website: https://andrewpla.tech Socials: @AndrewPlaTech Blog from Fred about our mentorship: https://allthingspowershell.blogspot.com/2018/12/the-roi-of-teaching-others.html?q=andrew+pla First PowerShell Summit blog post: https://andrewpla.tech/personal/powershell%20summit/2018/04/22/PowerShell-Summit-=-Expectations-Exceeded/ https://allthingspowershell.blogspot.com/2018/12/the-roi-of-teaching-others.html?q=andrew+pla https://andrewpla.tech/personal/powershell%20summit/2018/04/22/PowerShell-Summit-=-Expectations-Exceeded/ PowerShell Podcast Home page: https://www.pdq.com/resources/the-powershell-podcast/ Listen to the PowerShell Podcast: https://powershellpodcast.podbean.com/  

Kiosks are flooding the quick-service industry right now, from the biggest brands to fast casuals looking to scale. But what are the pitfalls and real benefits? Do they actually replace labor? Optimize sales? We'll break down the landscape, present and future, and the ins-and-outs of implementation and performance, with PDQ chief operating officer Eric Knott and GRUBBRR chief marketing officer Jarrett Nasca.

In this episode we bring you up to date with current events. Website: thefacthunter.com Email: thefacthunter@mail.com Snail Mail: George Hobbs PO Box 109 Goldsboro, MD  21636Show Notes:GMRS OPTIONhttps://strykerradios.com/ham-radios/gmrs-vs-ham-radio-which-should-i-choose/#:~:text=In%20short%2C%20as%20GMRS%20is,of%20the%20other%20bands%20besides. Canadian municipality now requires a QR code https://thecountersignal.com/canadian-municipality-requires-qr-code/ Philippines also US, European nations consider vaccinating workers exposed to bird flu https://www.reuters.com/business/healthcare-pharmaceuticals/us-european-nations-consider-vaccinating-workers-exposed-bird-flu-2024-05-27/ Chickens culled https://www.usatoday.com/story/news/nation/2024/05/29/bird-flu-updates-iowa-infected-chickens-alpacas/73892743007/ Chase Oliver https://x.com/EndWokeness/status/1794992462403957031 https://x.com/mazemoore/status/1795089209776021510 https://x.com/amuse/status/1795083779460985044 Lawmakers move to automate Selective Service registration for all men https://www.militarytimes.com/news/pentagon-congress/2024/05/23/lawmakers-move-to-automate-selective-service-registration-for-all-men/ Usury: The Crime of the Ages https://www.vtforeignpolicy.com/2024/05/usury-the-crime-of-the-ages AUDIO:  The 1969 Draft Lottery (Vietnam War) https://youtu.be/gl29gRRppBg?si=zLTWGkfUG93hADQm Restaurants going out of business Fuddruckers, Old Country Buffet, iHop, Buffalo Wild Wings. Applebees, Red Lobster, Denny's, Marie Callender's, Pizza Hut, Outback Steakhouse, Sbarro, MOD Pizza, Ruby Tuesday, PDQ, Joes Crab Shack, Bonefish grill, Casinos, Quiznos, Macaroni Grill, TGI Fridays, Boston Markets.  US nears deal to fund Moderna's bird flu vaccine trial https://www.reuters.com/business/healthcare-pharmaceuticals/us-nears-deal-fund-modernas-bird-flu-vaccine-trial-ft-reports-2024-05-30/

In this episode of the Restaurant and Retail Revel(ations) podcast, PDQ Chief Operating Officer Eric Knott shares how listening to your customers, testing your ideas, and caring about your people are part of the fast-casual restaurant's recipe for success.PDQ stands for “People Dedicated to Quality,” and true to the brand's name, the PDQ franchise goes to great lengths to ensure it ranks among the best fast casual restaurant options in the marketplace.Whether you're interested in why PDQ chicken could be a smart franchise investment for you, or to see how the brand's quality-first operations result in an irresistibly craveable menu, tune in now for Eric's insights!

PART ONERich is pleased with the performance but, in what would become a theme – frustrated that we didn't take our chances when presented. Neal thinks a win at St Mary's is inevitable and then we'll be off to Anfield to finish Klpp's FA Cup ambitions. Chip Shop Terry wonders if the wingers coming off was the wrong move for the match. Brett having sat with Pete during the game and discuss what was so good but where it went wrong with the substitutions and a first sight of Dennis shows us that he is going to need to get up to speed PDQ!Wendover as always is keen to see us do some business in the transfer window to build on a very solid foundation of a team. Neil joins us and asks the question – what will it cost us to recruit a player who ca play at the level we saw from Pollock today?COYH!This Podcast has been created and uploaded by Do Not Scratch Your Eyes. The views in this Podcast are not necessarily the views of talkSPORT.Huge thanks to all our Patreons:Chris Giannone,RichWFC2,Steve Holliman,Paul Fiander Turner,Sean Gourley,Lee Anselmo,John Parslow,Mark von Herkomer,Neil Silverstein,Steve Brown,Dave Lavender,Kasey Brown,Nipper Harrison,Boyd Mayover,Colin Payne,Paul Riley,Gary Wood,Karl Campion,Kevin Kremen,The Big Le – Bofski,Greg Theaker,Malcolm Williams,Bryan Edwards,Peter Ryan,Luka,John Thekanady - Ambassador of Dubai!!Jack Foster,Jason Rose,Michael Abrahams,Ian Bacon,Ken Green,Nick Nieuwland,Colin SmithAnt!!!!!& PDF Hosted on Acast. See acast.com/privacy for more information.

In this episode of Freight Nation: A Trucking Podcast, host Brent Hutto is joined by Aaron Dunn, Director of Sales and Marketing at PDQ America, and Michael Clements, President at PDQ America. Together, they discuss PDQ's story from one truck to a large brokerage, the journey that led to the Trucking for Millennials podcast, and the value they both have gained from hosting the show.

Romas waits forever for "pretty damn quick" from PDQ .Ducharme talks about the rock concert he attended the night before. https:/patreon.com/2als1podhttps://www.instagram.com/thetalkingdickscomedypodcast/https://twitter.com/DicksTwohttps://www.facebook.com/thetwodickshttps://www.facebook.com/The-Talking-Dicks-Comedy-Podcast-107101331446404Support the show

On this episode of the Just the Guys Podcast, the Guys start the episode with some chicken sandwich talk. The Guys debate whether PDQ has a better chicken sandwich than Chic-fil-a. The Guys kick off the episode with their first topic which is a viral video of some guys pouring up lean at a Top Golf. The Guys then get into a CRAZY situation that went viral on the TL of a woman outing a man for spreading STDs while knowing he has them. The Guys also go over the fact the guy came out and said that she was lying about it all and the Guys discuss how that is going to affect situations on the TL later down the road. Then the Guys get into a heated back and forth about celibacy and how Sommer Ray and Glorilla are announcing that they are saving themselves until marriage. They discuss how celebrities announcing their celibacy could be a finesse for attention. They also go over whether they would date someone who is celibate. The Guys wrap up the episode by discussing what is to come in episode 100! Thank you tuning into the podcast and we will be back next week with the next episode!   Check us out on other platforms! YouTube Channel: https://www.youtube.com/@JustTheGuys?sub_confirmation=1 Check us out on other platforms! https://linktr.ee/justtheguyspodcast  

Unlock the secrets behind the fast-food revolution with Eric Knott, COO of PDQ, as we discuss the art of enhancing the guest experience in the bustling restaurant industry. Learn how PDQ's dedication to quality goes beyond mouthwatering meals, delving into the heart of their team dynamics and community engagement. As we examine the ripple effects of business practices on both community and industry, you'll grasp how PDQ is setting a new standard for fostering lasting relationships and exceptional service.In this episode, you'll learn from Eric about:Daring operational choicesPivotal role of feedbackImpact of guest engagementMore!Thanks, Eric!

In the latest episode of Hospitality Hangout, Michael Schatzberg "The Restaurant Guy" and Jimmy Frischling "The Finance Guy" host Kep Sweeney, CEO of PDQ Restaurants. The guys start with the Tuesday trivia, revealing three facts about Kep, two of which are true and one false.Kep gives a brief background of himself and PDQ, sharing that the company has a presence in Florida and New York and is known for delivering non-QSR quality food quickly. He mentions PDQ's culinary ethos and its co-founders Bob Basham and Nick Reader.They talk about Sweeney's Wall Street days before delving into his career trajectory. Starting in restaurants, Kep worked with culinary legends and received an award from Julia Child before obtaining his MBA. He was then hired by Solomon Brothers and became a restaurant analyst, gaining experience with independent and multi-unit restaurants. He authored "The New Restaurant Entrepreneur" and has been involved in restaurant consulting, turnarounds, and process improvement.Kep then talks about his transition to PDQ, reflecting on Solomon Brothers' legacy with the hosts. They discuss the origins of major restaurant brands like McDonald's, and Kep provides insight into PDQ's beginnings, detailing how the company grew from a single location to 62. The founding story is explored, including how PDQ was created out of a need for healthier food options for kids.The discussion shifts to the specifics of PDQ's growth, including its corporate model and the unique challenges of franchising. Kep emphasizes the importance of developing operators who are passionate about their work and supported by quantitative analysis, aiming for a perfect day at PDQ with high-quality products and motivated staff. Check out the entire conversation for a deep dive into PDQ's organizational structure, customer-centric approach, data-driven decision-making process, technology adoption, and product innovation. It provides valuable insights into how modern restaurant operations can thrive in a competitive landscape by embracing innovation, agility, and customer-focused strategies.To hear the questions and the answers to Tuesday Trivia's “Two Truths and a Lie,” tune into this episode of Hospitality Hangout.

In the latest episode of Hospitality Hangout, Michael Schatzberg "The Restaurant Guy" and Jimmy Frischling "The Finance Guy" host Kep Sweeney, CEO of PDQ Restaurants. The guys start with the Tuesday trivia, revealing three facts about Kep, two of which are true and one false.Kep gives a brief background of himself and PDQ, sharing that the company has a presence in Florida and New York and is known for delivering non-QSR quality food quickly. He mentions PDQ's culinary ethos and its co-founders Bob Basham and Nick Reader.They talk about Sweeney's Wall Street days before delving into his career trajectory. Starting in restaurants, Kep worked with culinary legends and received an award from Julia Child before obtaining his MBA. He was then hired by Solomon Brothers and became a restaurant analyst, gaining experience with independent and multi-unit restaurants. He authored "The New Restaurant Entrepreneur" and has been involved in restaurant consulting, turnarounds, and process improvement.Kep then talks about his transition to PDQ, reflecting on Solomon Brothers' legacy with the hosts. They discuss the origins of major restaurant brands like McDonald's, and Kep provides insight into PDQ's beginnings, detailing how the company grew from a single location to 62. The founding story is explored, including how PDQ was created out of a need for healthier food options for kids.The discussion shifts to the specifics of PDQ's growth, including its corporate model and the unique challenges of franchising. Kep emphasizes the importance of developing operators who are passionate about their work and supported by quantitative analysis, aiming for a perfect day at PDQ with high-quality products and motivated staff. Check out the entire conversation for a deep dive into PDQ's organizational structure, customer-centric approach, data-driven decision-making process, technology adoption, and product innovation. It provides valuable insights into how modern restaurant operations can thrive in a competitive landscape by embracing innovation, agility, and customer-focused strategies.To hear the questions and the answers to Tuesday Trivia's “Two Truths and a Lie,” tune into this episode of Hospitality Hangout.

The critical issue of trust leakage. We're all guilty of focusing too much on acquiring new customers but neglecting customer retention. Providing clear delivery promises to your customers during the buying process is so important.In this episode, Jordan West sits down with guest Avi Moskowitz to discuss the challenges of building trust and improving customer experience in the e-commerce industry. Avi shares his insights and experiences in utilizing the PDQ platform to address these issues. Listen and learn in this episode!KEY TAKEAWAYS FROM THIS EPISODE:Supporting teams and giving them autonomyData-driven delivery promises and their impact on brandsLack of clear delivery promises leads customers to abandon purchases and turn to platforms like Amazon. Opportunities to improve trust and create a positive customer experienceThe Pareto principle and its consistency in businessAI learning and its similarity to human intelligence Addressing the challenge of building trust in e-commerceThe importance of quick delivery and increasing repeat purchasesThe focus on the "leaky bucket" phenomenonThe inefficiency and lost resources in acquiring and losing customersPDQ's focus on operational efficiency and delivery promisesShopify offers features and integration with shipping methods and carriers to provide data-driven delivery promises.Trust is crucial in business and should not be skipped over.Focusing on the checkout process can significantly impact profitability and customer retention.Recommended Tool:Fireflieshttps://app.fireflies.ai/ChatGPThttps://chat.openai.com/Pretty Damn Quickhttps://www.prettydamnquick.com/Recommended Book:Good to Greathttps://www.goodreads.com/book/show/76865.Good_to_Great 7 Habits of Highly Effective Peoplehttps://ati.dae.gov.in/ati12052021_1.pdfToday's Guest:Avi Moskowitz, is the founder of a website development company that specializes in bringing an Amazon-like experience to independent brands. In 2020, Avi and his team launched their own website on Shopify, but faced unexpected success due to the COVID-19 pandemic, resulting in hundreds and sometimes thousands of orders per day. This overwhelmed the team, leading Avi to spend most of his time writing apology notes for delayed deliveries. Determined to find a better solution, Avi and his co-founder, Leron, developed a platform that aimed to recreate the trust and customer experience found in physical retail stores. They understood that independent brands often lacked the resources to build trust and convey professionalism online, unlike e-commerce giant Amazon. Avi's company seeks to bridge this gap by providing a comprehensive and trustworthy online shopping experience for independent brands.Connect and learn more about Avi and Pretty Damn Quick here: LinkedIn: https://www.linkedin.com/in/moskowitzavi/Website: https://www.prettydamnquick.com/Get 5 Offers for 2 Products (10 in total) along with 10 highly engaging tried and true creatives, 30 captivating headlines, descriptions, and ad texts sent to you for only $99. Go to We love our podcast community and listeners so much that we have decided to offer a free eCommerce Growth Plan for your brand! To learn more and how we can help, click here: upgrowthcommerce.com/grow Join our community and connect with other eCommerce brand owners and marketers! https://www.facebook.com/groups/secretstoscalingpodcast

On today's MJ Morning Show: Sinead O'Connor Madonna's illness not in the news? Computer Oaf Morons in the news Fester saw a vehicle driving erratically on I-275... again Most famous dogs Disgusting candy  Roxanne and her family Video-bathing in bakery goods Guilt tipping... now gone further Sinead O'Connor Michelle-the "Nothing Compares 2 U" story How to tell if your neighbor is a serial killer One of the latest online challenges....false kidnapping reports Bodycam footage where HCSO took kids into custody for a BB gun near a school campus A guy was hit in the face with a cel phone... on a roller coaster Leprosy is making  a comeback? 10 patty burgers Roxanne's pants too tight? PDQ in studio Cross-Atlantic flight served KFC piece to each passenger A flight attendant with an itchy trigger to turn back to airport.

We went to Luke Combs, Laney Wilson needs to sell her pants, old people hate concerts, John had a birthday, Mica gets car sick, and you know the quality of people by their teeth. Also, smokin' on tat broccoli, butter up the buns, the taco never makes it home, what does PDQ mean and the cougar beer. All that and more on this episode of The Born Stupid show.

Good morning and happy Tuesday! Lots to win and tons of fun to have. After the show today, Joe and Jed are going to PDQ to try out some of their new menu items! The question is: which non-breakfast fast food item would you eat for breakfast?!

In this episode podcast host Mandy Wolf Detwiler sits down with loyalty experts Larry Fiel and Mike Reinecker of PDQ, and Russ Lehmann, co-owner of Little Italian Pizza in Naperville, Illinois, to learn how the pizzeria is finding success with its loyalty program.

Dr. Shannon Westin and her guest, Dr. Harvey Max Chochinov, discuss his article "Intensive Caring: Reminding Patients They Matter." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and thank you so much for joining us for another JCO After Hours podcast. This is the podcast that gets in depth in manuscripts published in the Journal of Clinical Oncology. I'm your host, Shannon Westin, GI oncologist by trade and honored to serve as the Social Media Editor for the JCO.  And today we're going to be discussing a really exciting paper in the Comments and Controversies section called “Intensive Caring: Reminding Patients They Matter.” This has been recently published, and I'm so excited to have the author of this paper join us today, Dr. Harvey Max Chochinov, who is a distinguished professor in the Department of Psychiatry in the University of Manitoba, senior scientist with Cancer Care Manitoba Research Institute, and the cofounder of Canadian Virtual Hospice.   Welcome. So great to have you today.  Dr. Harvey Max Chochinov: Thanks, Shannon. Dr. Shannon Westin: And please note neither of us have any conflicts of interest, so we'll just get right started. So first, I just wanted to explore the title of your paper, “Intensive Caring.” Can you describe a bit about what that means? Dr. Harvey Max Chochinov: Well, we know that in medicine there are occasions when patients find themselves in such medical dire straits that they require intensive care. They've reached the stage where they certainly can no longer help themselves, and they require this kind of intensive approach that medicine is capable of offering. But intensive caring is meant to acknowledge that there are times when patients can be in such dire emotional straits that we need a way of being able to address that degree of abject suffering. So the idea of intensive caring was to try and provide language to describe that approach and, within the paper, as we're going to discuss, also to describe the ways in which we can actually deliver that kind of caring. Dr. Shannon Westin: Can you tell me a little bit about kind of when and where your inspiration for this work arose? Dr. Harvey Max Chochinov: The inspiration actually came from Dame Cicely Saunders. Dame Saunders was the founder of the modern hospice movement. There's a famous quote or adage that she said: “You matter because you are you, and you matter to the last moment of your life.” And this has really become kind of a central philosophical tenet of palliative care. But yet it struck me that although it describes this philosophical approach, implicit is also perhaps a clinical approach which says how do we, in fact, show patients—how do we demonstrate to patients or practice medicine in a way that actually affirms that patients matter? So that's where the title came from: “Intensive Caring: Reminding Patients They Matter.” Dr. Shannon Westin: There are so many pieces to this. I was so struck by what you said about these emotional dire straits. That's the best way I've ever heard it described. I feel like one of the major areas is that loss of hope and that feeling that you don't matter anymore. So what can we do? How do we, as practitioners, act and intervene to change that feeling? Dr. Harvey Max Chochinov: That's a wonderful question. The paradigm of contemporary medicine is we examine, we diagnose, and we fix. And yet, when it comes to addressing many elements of human suffering, it doesn't lend itself well to that paradigm because, of course, we know that there are things that are beyond the realm of fixing. So what we need, then, is to understand a way of approaching patient care where fix really is beyond our reach. How do we do that? It's by understanding that by being with the patient, by things like non-abandonment, all of these things are ways of maintaining patient engagement.  There was a wonderful study a number of years ago by Kelly Trevino in which she looked at the associations between suicidality and the intensity and the quality of the connectedness with the medical oncologist. And it turns out that that was the single most predictive factor regarding suicidality over psychological interventions or over psychotropic medication. So the way in which we start to address this kind of abject suffering, maintaining hope, is to understand that and acknowledge that there are things that we may not be capable of fixing. But the provision of intensive caring—and, again, the elements of intensive caring that I described in the article—give us ways of being able to be with patients that don't require fixing but require presence, require involvement, require ongoing commitment to the well-being of that individual.  Dr. Shannon Westin: This is a perfect segue because I was struck by that tenet of non-abandonment, you know, really committing to ongoing care. I wonder about this because we do have patients that transition to hospice, and often, in our group, they'll have an entirely new care team. And that's just part of that intensive caring that the hospice group provides. But I guess, in seeing it in these terms, I'm feeling a little bit like that may not be the ideal way for that transition to happen. So any thoughts on how we kind of combat that? Or how can we work together with hospice so that the patient feels still supported but still gets that hospice care that they so desperately need? Dr. Harvey Max Chochinov: Oh, for sure. Well, I mean, listen, we know that transferring of care is a technical task that can be accomplished by a single stroke of our keyboard on our computer. We transfer care. But there's nothing technical about the issue of caring, connectedness. And so it's unrealistic, and I don't think patients expect that all expertise resides in the hands of one individual or one team. But the reality is that when we've been looking after somebody for days, weeks, months, even years and they now have to transition to other care providers, although care can be transferred, I think there is still this human expectation of ongoing caring.   And caring doesn't necessarily require a great deal of time. It can be accomplished in really nuanced and subtle ways that really, I think, are within our grasp. Picking up a telephone, dropping by for a visit, putting a note in the mail simply to acknowledge that “I understand you're in hospice. Just want you to know that you've been on my mind. Hope things are going as well as they can for you and your family.” That demonstrates continued caring. It doesn't raise expectation that I, your medical oncologist who know you very well, am going to now intervene and take over your care. Dr. Shannon Westin: That's perfect. And I'm actually taking notes myself to—have a couple patients that I need to call today. So moving on to some of the other tenets, the Patient Dignity Question was really, I felt like, a revelation for me. It's so simple and so straightforward, and I feel like many of us, myself definitely included, don't feel like there's enough time, right, to dig into the details of every patient, kind of where they are in their process. Do you think this is something that everybody should implement today? Dr. Harvey Max Chochinov: So maybe backing up just for listeners to understand that the Patient Dignity Question asks patients, “What do I need to know about you as a person in order to provide you the best care possible?” We have done studies of the Patient Dignity Question, or PDQ, and there have been multiple studies and multiple translations around the world, probably the largest study being one that came out—Hadler, first author—several thousand patients at Memorial Sloan Kettering who were asked the Patient Dignity Question as part of the regular kind of palliative care consultation. I think the message that I take out of the PDQ research is that personhood should always be on our radar. And the reality is that if we don't understand at least the essence of who that person is, we can give lip service to providing person-centered care and lip service to maintaining dignity and all of those wonderful things that we say in position statements, but none of it will ring true if we don't have personhood on our radar. And it simply means that we need to be mindful of personhood.  I've asked patients, “So what do I need to know about you as a person to take the best care of you possible?” I've had people tell me, “I'm afraid to die alone.” I've had people tell me, “I am the victim of childhood sexual abuse.” I've had people tell me, “I'm a survivor of the residential school system.” One man said “I'm a former department head of medicine.” In fact, he was just a lovely man. He said when he was being treated for his cancer, he wanted to hang a sign on his bedpost that said, “PIP, Previously Important Person.” But what it says to me is that if we fail to acknowledge personhood, then essentially we're operating in the dark. When you have that kind of information about personhood, it just changes the way you see and experience that person, which makes for better patient care. Families are more satisfied. There's less discordance when it comes to goals of care, less likelihood of litigation because the reason that most people litigate is not because of medical misadventure. It's because they don't feel like they were treated like a person. They somehow feel like that was not acknowledged.   The other interesting piece of data out of the PDQ research is that when clinicians acknowledge personhood, they also report greater job satisfaction. So the reality is—and we know that one of the signs of burnout is emotional disengagement. So what our research has found is that if you give clinicians a way of at least maintaining some emotional engagement by finding out who this person is, not only are patients and families happier, but healthcare providers report greater satisfaction in the work they do. So the short answer is “Yes, I think we should be putting personhood on our clinical radar and finding ways that are feasible of making that happen.”  Dr. Shannon Westin: There's so many interesting tenets in this article and so many parts to the intensive caring. Some do seem to be elements of palliative care practice as well. So how would you say this is different or complementary?  Dr. Harvey Max Chochinov: I'd say indeed you're correct. I mean, some of the elements are probably ones that people in palliative care would recognize. And I don't necessarily think that that's a criticism or necessarily a bad thing. If some elements of intensive caring are accused of being old wine in a new bottle, a new bottle is something that can be very attractive. And if this can bring people back to understanding the human side of health care, well and good. I suppose what is unique about intensive caring are the constellation of elements that are described in the article—and all of the elements, by the way, are empirically based. So the article does lay out various elements of intensive caring and points out the empirical basis of each of those elements.   I think maybe the other thing that's unique about intensive caring is it begins to provide us a language for ways of being able to approach patients who are in these circumstances. Usually, in the face of this kind of abject suffering, our temptation is to feel the need to withdraw, maybe feelings of impotence, maybe feelings of failure. So intensive caring addresses all of those head-on by saying here is a way that you can effectively be with your patients, that you can mitigate their suffering, without feeling that your mandate is to examine, diagnose, and fix. It is a different paradigm, which says you can be present with and provide comfort to. Dr. Shannon Westin: Great. Now, what about therapeutic humility? Can you speak of it like that? I think many of us come into medicine because we like fixing problems. So how does this concept turn the paradigm on its head? You kind of already talked about it a little bit, but I think it's important to mention specifically.  Dr. Harvey Max Chochinov: I think anybody who's been practicing medicine for any period of time has had the experience of confronting things that don't lend themselves well to fixing. Let's take the instance of somebody who is near end of life, or even the instance where a patient has died, you're standing outside of their room, and the family is still there. You have some choices. You can either withdraw, just say, “There's nothing I can do; I've got other things that are more pressing,” or you can go into that room. Now, when you go into that room, you need to be able to put on the shelf any idea that you have the right words that are going to fix what ails this now bereft family.  But I think wise and seasoned clinicians—and I would put to you, see, clinicians who have therapeutic humility would say you go into the room. Why? Because being there, just being present with, acknowledging the loss—and it's not about what you say. Again, if you feel like you have to wait till you have the right words, you never will go in there. But if you just go in empty-handed and allow yourself to be in the presence of that kind of suffering, what any clinician who does that will say is it's of critical importance. It matters. It makes a difference. And so that is one example of therapeutic humility. And again, there are others because there is so much that we deal with. For those of us who deal with patients with chronic illness or incurable illness, the fact is that if you're not humble, you're going to find yourself perpetually feeling like you are failing, like you are not meeting patients' expectations. What patients expect is not that you can fix what's not fixable. They expect you to be involved. They expect you to care. You will be there for them in times that are tough. Those are elements of intensive caring that are worth taking forward into practice. Dr. Shannon Westin: Well, this has been so educational. I feel like I could talk with you for another hour. But why don't we end by just speaking about the next steps for this work, and how can we make everyone aware aside from publishing in the JCO and putting out this podcast? What else can we do? Dr. Harvey Max Chochinov: Well, hopefully, the approach gives people both the language and the ways in which we can start to implement this in practice. I would hope that it kind of catches or takes hold in medical curricula, but not only in medicine but really in any setting where individuals are being trained who have access to patients. This is not just about doctors. This is about anyone and everyone who has patient contact because the reality is that irrespective of whether you're the medical receptionist or the person making the first incision, you have the ability to either affirm or disaffirm the personhood of the individual that you're in the presence of. That's both a responsibility and, as well, an opportunity. So hopefully, dissemination of this work spreads word that this is an opportunity that we can take hold of, hopefully for the betterment of patients and families and healthcare providers themselves.  Dr. Shannon Westin: Great. Well, thank you so much. You've been such an inspiration. I can't wait to start utilizing these in my clinic just tomorrow. So I really appreciate you, and I know all our listeners do as well.   Listeners, we appreciate you. Thank you so much for tuning into JCO After Hours. Again, we were discussing the Comments and Controversies article “Intensive Caring: Reminding Patients That They Matter.” I hope you enjoyed it. Please do check out the website and check out any other podcasts that are ongoing and let me know what you think. Have a great day.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Episode 5 description: This is the next installment in our war on science series and we're looking at the first episode of the Netflix documentary (un)Well "Essential Oils".  This trend is a little too soothing for us to go too hard at the concept, but never fear!  Marc and I have plenty to say about a couple of the key figures featured in this episode.  Dr. Z, my dude, we are coming to drag you!  Listen for digressions into gangster rap, a little bit of our personal experience with western medicine and as always, Marc tells jokes.   Thank you for listening to us each week.   Monroe, Rachel, Sheila Marikar, and Judith Thurman. “How Essential Oils Became the Cure for Our Age of Anxiety.” The New Yorker, 2017. https://www.newyorker.com/magazine/2017/10/09/how-essential-oils-became-the-cure-for-our-age-of-anxiety. Integrative, PDQ, Alternative, and Complementary Therapies Editorial Board. “Aromatherapy With Essential Oils (PDQ®).” PDQ Cancer Information Summaries [Internet]. U.S. National Library of Medicine, October 24, 2005. https://www.ncbi.nlm.nih.gov/books/NBK65874/. https://www.youtube.com/watch?v=GlGCc99ZXjs Sashin, Erica. “(Un)Well.” Netflix Official Site, August 12, 2020. https://www.netflix.com/watch/81076172?trackId=14170289. https://www.youtube.com/watch?v=q1Km6E_0sLg --- Support this podcast: https://podcasters.spotify.com/pod/show/marc-snediker/support

As an eBay seller, you need to keep up with what's hot on eBay at any given retail moment, because you may have an in-demand item in stock and need to get it listed ASAP — or source it PDQ! In this episode of I Love to Be Selling, you'll discover a trending product so popular that more than 8,000 of them have sold within the last 30 days. Tune in to find out what it is that shoppers are searching for right now and how you can catch this profitable wave. You'll also get access to I Love to Be Selling's free guide What Sells on eBay for Mother's Day! It's 12 full pages power-packed with giftworthy goodies that moms will love. Download your complimentary copy at https://ilovetobeselling.com/webinars-and-workshops/what-sells-for-mothers-day/. I'm Kathy, and I love to be selling!

There's nothing more frustrating than listing an item that doesn't sell. In this episode of I Love to Be Selling, you'll discover small tweaks that can give your sales a BIG boost! Tune in to learn savvy strategies for revising nonperforming listings PDQ to get them sold ASAP. (Hint: Think details, as in keywords and item specifics.) You'll also gain access to I Love to Be Selling's newly updated free guide Dominate eBay Search & Win More Sales! It's chock-full of proven, actionable info and tips for getting your items found by buyers. Download your complimentary copy at https://ilovetobeselling.com/webinars-and-workshops/dominate-ebay-search-tips/. I'm Kathy, and I love to be selling!

According to a recent PDQ survey, 85% of people who manage devices are a team of 1. Many of our guests have a small scope to their job: they manage Macs and/or iPhones. But many in IT manage, well, everything. That means being a jack of many traits: knowing just enough about networking, switches, routers, every piece of software used in an organization, budgeting, or whatever is on the docket at the moment. Today we're going to cover what it's like to cover such breadth with Ylan.  Hosts: Tom Bridge - @tbridge777 Charles Edge - @cedge318 Marcus Ransom - @marcusransom Guests: Ylan Muller - @HeyItsYlan Transcript: Click here to read the transcript Sponsors: Kandji Kolide dataJAR Watchman Monitoring If you're interested in sponsoring the Mac Admins Podcast, please email podcast@macadmins.org for more information. Get the latest about the Mac Admins Podcast, follow us on Twitter! We're @MacAdmPodcast! The Mac Admins Podcast has launched a Patreon Campaign! Our named patrons this month include Weldon Dodd, Damien Barrett, Justin Holt, Chad Swarthout, William Smith, Stephen Weinstein, Seb Nash, Dan McLaughlin, Joe Sfarra, Nate Cinal, Jon Brown, Dan Barker, Tim Perfitt, Ashley MacKinlay, Tobias Linder Philippe Daoust, AJ Potrebka, Adam Burg, & Hamlin Krewson

The Patient Dignity Question (PDQ) is the best question that you will ever ask your patient. It will supercharge your doctor-patient connection and give you key information that you might otherwise have missed.Listen and try it out in your practice.If you have a colleague who would benefit from learning about the PDQ, please forward the episode to them.Reach out anytime!Dr. ChiaramonteDo you wish that you had more tools to give great care to your patients with complex or serious illness? A new CME program will be starting soon that will give you the skills and confidence that you're looking for to help your most challenging patients. Sign up and I'll let you know when the next course is open: https://trainings.integrativepalliative.com/tiipm-keep-in-touch. Programs will also be starting soon for loved ones of people with serious illness. Sign up at the link above if you'd like to know when registration is open.Please review this podcast wherever you listen and forward your favorite episode to a friend! Thanks for helping me spread the word about heart-centered care for people with complex and serious illness.

We're back with more chicken sandos! Chick Fil A vs PDQ, who will win?And this boys get ready for Halloween.Follow us on IG @bunkerboyz_podcast

Here at the Pilot Episode, we love acronyms, so listen to this show ASAP and PDQ you'll find you're having a good time. If you like Marvel movies, that is. Settle in folks, you're in for a trip!

FRIDAY 10/14/22: A TikTok user cries over a couch purchase. A mother is in legal trouble after letting her 10-year-old son get a tattoo. A popular restaurant MAY be serving Kraft macaroni and cheese. The FDA goes after CBD, PDQ.

On this weeks episode Ed shares his disappointment with PDQ as of late. Nate talks about Orlando City's recent win streak and the fellas dive into what they've been watching on stream as of late.  

NFL Hall of Famer Derrick Brooks and Jim Kamis from PDQ stop by the studio to discuss PDQ's 17th location and its fundraiser for the Derrick Brooks charity. Plus, Brooks weighs in on the upcoming Bucs season.

Chrome quashes another zero-day browser bug. Two big-time cybercrime stories. A 2FA phishing scam that arrived PDQ. Chester swarmed by bots on Twitter. Original music by Edith Mudge Got questions/suggestions/stories to share? Email tips@sophos.com Twitter @NakedSecurity Instagram @NakedSecurity

The year is 2053. The tabs-vs-spaces wars are long over. Ron Evans is the only Go programmer still alive on Earth. All he does is maintain old Go code. It's terrible! He must find a way to warn his fellow gophers before it's too late. Good thing he finally got that PDQ transmission system working…

The year is 2053. The tabs-vs-spaces wars are long over. Ron Evans is the only Go programmer still alive on Earth. All he does is maintain old Go code. It's terrible! He must find a way to warn his fellow gophers before it's too late. Good thing he finally got that PDQ transmission system working…

In this episode I share how you don’t have to take 14+ years like I’ve had to in order to build a big list. With the tools, data access, and techniques here at TW3 you can have a big list and build a strong band PDQ! After seeing a misplaced… The post Episode 523 – The loot is in the list! How to build a big list fast! first appeared on terrywilson3.com.

This week Michael's out and Nolan Grush is IN! Nolan Grush is the Carrier Relations Manager for PDQ America, so it was great to "talk shop" after a long week moving loads. In this conversation you'll hear how Nolan got into freight and logistics, what he does for PDQ, what frustrated him about today, what makes a great dispatcher and great freight brokerage and much more. Enjoy! 

This week, Taylor, Doug Jordan and Taddea Richard discuss Ben Affleck's snail handling, A woman who found something inside herself, PDQ's new menu items, the countdown to Queen Elizabeth's death, a study that explains why we hate old people and much, much more! Brand new segments include Taddea's Thoughts: On the War in Ukraine, and Our Week's: Guide to Spring Break!

If you were to make a mockumentary for your company, what would it look like? How would you poke fun at workplace norms, demotivating leaders, and most importantly, yourselves? Many leaders scoff at the idea of getting their teams together to create content rooted in irreverence, but PDQ.com did just that (3 times, actually) with tongue-in-cheek documentary-style videos on their website. Where most companies post self-inflating videos about how awesome it is to work there, PDQ.com takes the opposite route, while somehow proving that it's a place where you CAN laugh at work. Co-founder Shawn Anderson joins the podcast to talk about these videos, the value of irreverence in leadership, creating content for HUMANS, and his "Grandpa Story" that asks the question "Do you cartwheel into work AND backflip out?" Check out the mockumentary videos below: https://www.youtube.com/watch?v=ezZg3ZC_-5g&t=316s https://www.youtube.com/watch?v=U7HKpgT42Ew https://www.youtube.com/watch?v=tl63Vz9Lo3U Learn more about PDQ.com at... well... pdq.com About The Podcast: You Can't Laugh At That is a podcast launched by comedians David Horning and Steve Mers to prove that anything can be funny in a world that often takes itself too seriously. David and Steve are obsessed with the art and science of comedy and why we laugh, so this podcast was started to prove that when approached with the right intent, perspective, and delivery, you CAN laugh at that. You Can't Laugh At Work was started as part of David's mission to prove that having a sense of humor is not only nice to have, it's crucial, so he invites leaders of top workplaces to share their stories of disruption, failure, and thinking outside the box to prove that with the right culture, you CAN laugh at work. Support the podcast and our guests by visiting watercoolercomedy.org/podcast and purchasing an album, book, or your own podcasting equipment Visit patreon.com/youcantlaughpod and become a Patron for exclusive access to bonus content. Follow us on social media for updates, clips, and comedy tips: twitter.com/youcantlaughpod facebook.com/youcantlaughatthat Follow David on Twitter: https://twitter.com/thedavidhorning Instagram: https://instagram.com/thedavidhorning LinkedIn: https://www.linkedin.com/in/watercoolerdavid Produced by Water Cooler Comedy - http://watercoolercomedy.org​ Music by Producedbyzip - https://producedbyzip.bandcamp.com

PDQ.com is all about keeping it real. Not many companies can be praised for that. It's a rare and unique skill that the founders nurtured and ultimately turned into the main driver behind content creation for their audience. Before they had their eye on podcasting, they launched a webcast that they still have going every single week. Kelly Hammer, Content Marketing Manager at PDQ, joins Growth Marketing Camp to teach our listeners how to create content that forges a strong community. He also shares his curiosity to explore the world of TikTok and the importance of turning your customers into evangelists and promoters. Dig in!

PDQ.com is all about keeping it real. Not many companies can be praised for that. It's a rare and unique skill that the founders nurtured and ultimately turned into the main driver behind content creation for their audience. Before they had their eye on podcasting, they launched a webcast that they still have going every single week. Kelly Hammer, Content Marketing Manager at PDQ, joins Growth Marketing Camp to teach our listeners how to create content that forges a strong community. He also shares his curiosity to explore the world of TikTok and the importance of turning your customers into evangelists and promoters. Dig in!

How do you talk to patients about medicinal cannabis? Dr. Ashley Glode (University of Colorado) moderates a discussion on effectiveness and safety, misconceptions and more. Featuring Drs. Ilana Braun (Dana-Farber Cancer Institute), Daniel Bowles (University of Colorado), and Kent Hutchison (University of Colorado). Subscribe: Apple Podcasts, Google Podcasts | Additional resources: education.asco.org | Contact Us Air Date: 1/19/22   TRANSCRIPT ASHLEY GLODE: Hello, and welcome to ASCO Education's podcast on medical cannabis, also referred to as medical marijuana. My name is Ashley Glode, and I am an associate professor with the University of Colorado School of Pharmacy. It's my pleasure to introduce our three guest speakers Dr. Ilana Braun is chief of the division of adult psychosocial oncology at Dana-Farber Cancer Institute, and an assistant professor of psychiatry at Harvard Medical School. Dr. Daniel Bowles is an associate professor of Medical Oncology at the University of Colorado. We're also joined by Dr. Kent Hutchison, a professor of psychology and neuroscience at the University of Colorado Institute of Cognitive Science. Let's start with a simple but fundamental question. What is medical cannabis or medical marijuana? ILANA BRAUN: So Ashley, I think that's such a great first question. I think of medicinal cannabis as herbal nonpharmaceutical cannabis products that patients use for medicinal purposes. And typically they're recommended by a physician in compliance with state law. DANIEL BOWLES: Dr. Braun makes a really good point. And I think it's important to know when patients are referring to medical cannabis, there's a wide variety of different things they could be referring to. Sometimes they would be referring to smoked herbal products, but there are also edibles, tinctures, ointments, creams, all sorts of herbal-based products that people use and call medical cannabis. And then there are also the components that make up medical cannabis-- largely, the cannabinoids. And I think the big ones people think about are THC and CBD. And sometimes those are used in their own special way. So I think that it's important for us as providers to be able to ask our patients, what is it that you mean when you say, I'm using medical cannabis? ILANA BRAUN: I think that's such a great point. And I will add I think it's also important to remember that when you offer a medicinal cannabis card to a patient, you're giving them license in most states to access any number of products. It's not an insurmountable challenge, but it's a whole new world for traditional prescribers who are used to writing a prescription and defining what is the active ingredient, how often a patient will take the medicine, by what means. DANIEL BOWLES: I think the other thing we need to be very aware of, as hopefully people are listening to this across the country and elsewhere, is the laws vary wildly from jurisdiction to jurisdiction about what consists of medical cannabis, who is allowed to use it, and in what quantities. So I think it's really important that as we learn about these and we think about these, we think about how they apply to any of our specific situations in which we live in practice. KENT HUTCHISON: So it's interesting-- just follow up on what Dr. Braun and Dr. Bowles, what they're saying, those two words-- right-- medical and cannabis. I think the medical part is somewhat easier because it can refer to the reason the person is using. Are they using for medical reasons are they using for recreational reasons, even though that's a blur? But the cannabis part I think is what's really complicated. And this is what Dan was getting at. All the different products, all the different cannabinoids, I mean all the different bioactive terpenes and everything else in the material, all different forms of administration. That is where it gets super complicated to really define what that is. And then of course, there's so little research we don't really know what all those constituents do. ASHLEY GLODE: Now that we kind of have a little bit of familiarity with medical cannabis, can you comment on adult use cannabis and what that might mean for a patient? ILANA BRAUN: Ashley, I think it's a really good question. And in some of the early research I did to try to understand where medicinal ended and adult use began, or adult use ended and medicinal began, I began to discover a theme that emerged, which is they sort of blend into each other often. In other words, some of the oncologists that I spoke to believed that it was not such a bad thing for a patient with serious illness, and pain, and many other symptoms to have a sense of high or well-being. And conversely, when I spoke to patients using cannabis, sometimes a cancer patient used medicinal cannabis for enjoyment, and sometimes they used it for symptom management, and sometimes they used it for both. And so I think it is somewhat of a slippery slope between the two. Would you agree? DANIEL BOWLES: I think there are definitely blurred lines between the two. I think that the advantages of what most states would recognize as medicinal cannabis is usually they're less expensive, patients can use them in larger quantities. There are certain advantages. But there's also paperwork that goes along with medicinal cannabis that some patients don't feel comfortable with. Or particularly I think when you have a patient who's interested in trying cannabis or a cannabinoid for the first time, they might not want to go through all the extra steps required getting that medical marijuana card, whereas adult use, I think people feel more comfortable, at least in my state, sometimes walking into a dispensary to discuss the options with people who work at the dispensary and then get it from more of an adult use or recreational cannabis initially. And then if that's something that they find helpful for their symptom management, to then take those extra steps and try to get a medicinal card. ILANA BRAUN: I agree with Dr. Bowles that the target symptoms or the target effect is often similar and access can differ. KENT HUTCHISON: Yeah. Just to chime in, I agree. I agree also. It's definitely-- the lines get blurred. The recreational user might also appreciate-- for example, college students, I hear them say a lot of times that they appreciate some of the anxiety-reducing aspects-- right-- even though they're not necessarily a person who has an anxiety disorder. And then of course, patients appreciate a slight increase in euphoria or positive affect, and what does that mean? Is I mean they're also using for recreational reasons? Or is that completely, I guess, legitimate? On the other hand, there are sometimes I feel like when-- especially on the recreational side-- when people are using for the more psychological effects, the sort of psychotropic effects, I know sometimes the medical patients refer to that as being a little bit loopy as a side effect. So I feel like there's definitely some blurred lines. And maybe there are some places where we can think about in perhaps in a less blurred kind of way. ASHLEY GLODE: How often do you guys have a patient ask you about medical cannabis? And what are the most common questions they might have for you? ILANA BRAUN: In my psycho-oncology practice, patients frequently tell me they're using cannabis, often with good effect and minimal side effects for polysymptom management-- for instance to address nausea, or pain, or poor appetite, or sleep, or mood, or quality of life. But they don't ask me a lot of questions. For instance, one of my longest-standing patients. A man with metastatic cancer and gastroparesis. Vaporizes cannabis before meals to keep his weight up. And many of my patients also use cannabis as cancer-directed therapy. And for these patients, side effects can sometimes be more pronounced. For instance, I have a lovely patient with metastatic cancer who follows a Rick Simpson protocol. So what is that? That's an online recipe marketed with an antineoplastic claim. And so this patient targets hundreds milligrams of cannabinoids daily. And with such high cannabinoid doses, she sometimes feels spicy, or out of it, as she describes it. And then I had another patient who targeted high daily doses and developed a debilitating nausea and vomiting that was initially diagnosed as chemotherapy-induced nausea vomiting because it was so hard to tease out in the setting of so many medicinal agents, what was what. But the symptoms resolved completely within weeks of the cannabinoids being halted. And so as I mentioned, what's notable about all three of these patients, and many of the others I see, is that they are quite open with their oncology teams and me about their medicinal cannabis use. But they don't seem to rely me or other members of their oncology team for their therapeutic advice . We insert ourselves when we see potential harm, but much of the decision-making seems to be made-- I don't know in the naturopath's office, at the dispensary counter, or by trial and error. And this anecdotal experience in my practice is borne out in my research findings as well. Patients are just not getting the bulk of their cannabis therapeutics information from their medical teams. DANIEL BOWLES: In my clinical practice, I am asked about cannabis or cannabinoids a fair, amount often in the context that Dr. Braun is describing, where a patient is coming in and they're already using a cannabinoid or they are planning on doing it and they just want my opinion. And I think unlike talking about more conventional cancer-directed therapies where they really rely, I think, on their medical team for information and guidance, we are often more a supplement I think in terms of information. In terms of the patients who come to ask me about cannabis or let me know that they're using cannabis, it's a very wide selection of people. I see young people, old people talking about it, men, women, a variety of different malignancies. So there really is a lot of usage or are thought about usage of cannabis or cannabinoids amongst our cancer patients. I think if you look at the studies, they'll tell us that depending on where we're working, anywhere between 20% to 60% of patients have used cannabis in the last year to help manage some sort of cancer-related symptoms. And I think the other thing that is notable is you'll find people asking about cannabis or cannabinoids who I think we might not have otherwise expected. So for instance, Just this past week, I had a patient with anaplastic thyroid cancer in his 70s, and his daughter was wondering whether he could try CBD to help with his sleep and anxiety. She wanted to make sure that it wasn't going to interact with this cancer therapies. And I appreciated her bringing it up, and we could have a frank discussion about the pluses and minuses of it, just like we might any other therapeutic intervention. So I think that particularly as the laws have changed across the country, more and more people are willing to tell us that they're trying cannabinoids and cannabis than maybe would have even 10 or 15 years ago. KENT HUTCHISON: I think in an ideal world, patients would be talking a lot more with their physicians about this topic. And I think unfortunately that a lot of people do get their information from dispensaries. From the media, from social media, from their kids, and from whoever. And I think that's something that I hope will change in the future. DANIEL BOWLES: In terms of questions that I'm often asked, I'll be asked if it's going to interact with their cancer treatments, in terms of making their medications more or less effective. I do get questions about how I think their cannabis use might affect some of their symptoms. I get questions about other drug-drug interactions-- let's say, interactions with opiates, or benzodiazepines, or some of these other medications that a lot of our patients are on. ASHLEY GLODE: In a recent survey 80% of medical oncologists who discussed medical cannabis with their patients, 50% recommended it in the past year, but only 30% felt knowledgeable enough to make recommendations. What do you guys think needs to be done to address this knowledge gap? And what resources do clinicians have to get and stay informed? DANIEL BOWLES: So I'm a big fan of the NCI's PDQ as a great resource. It has a fairly objective information about cannabis and cancer specifically. So I think that's a nice reference for people who are interested in getting an initial overview on the topic. I think there are also a number of different educational programs. I know the University of Colorado, for instance, has a Cannabis Science Master's and also a certificate program. So there are courses available for people who want to educate themselves more on this topic. ILANA BRAUN: Yeah. I guess when I think about what needs to be done, I think that cannabis needs to become a routine part of medical training curricula and CME programs. I think that a federal funding for high-quality clinical trials and a loosening of federal restrictions on accessing study drug were to occur, that would be really a big boon for the medical community. And my colleagues on this podcast I know are doing some very creative pragmatic clinical trials naturalistic studying what is happening in the field. And I am doing clinical trials using an FDA-approved version of cannabinoids. But it's still very hard to study whole-plant cannabis in a form that is sort of a standardized trial drug in a cancer patient. And then when I think about where I would begin to read, I don't think there is a single source, unfortunately. But a great place to start reading is actually a project that Dr. Hutchinson was a part of, which was an expert panel that was assembled by the National Institute of Science Engineering and Medicine in 2017. And they produced a monograph on the health effects of cannabis and cannabinoids. And it's several hundred pages long, including sections devoted just to oncology. So in other words, there is scientific evidence to evaluate, and it's sizable. DANIEL BOWLES: The Austrian Center for Cannabinoid Clinical and Research Excellence also is a helpful resource. One of the nice things about that is they actually give some dosing suggestions or ideas for people who really don't quite know where to start. Right now, there aren't a lot of people in that position to say, here's how it should be done. Here's how it gets dosed. Here are the data to support those decisions. And so the folks in the next level of training don't learn it in the same way that we have learned how to prescribe other medications. And they can't then lay it down. So because the data are scant, in some respects, and particularly for herbal products that So. Many of our patients are using, I think it falls outside the medical model that we've all become so used to using to learn how to take care of patients. And I think that's one reason that so many oncology providers feel interested in learning more about this topic, but don't feel comfortable giving patients guidance on how to use them. KENT HUTCHISON: So both Dr. Braun and Dr. Bowles identified some of the key resources out there. And certainly the training issues that Dr. Bowles just talked about are important. And I do want to emphasize the one thing that Dr. Braun mentioned, which is basically that we do-- we lack research and we lack data on some key important issues, like dosing, for example. What dose is effective? So cannabidiol has been out there for a long time, but what dose is effective for what? We don't know, right? So we definitely lack research. And there are definitely obstacles to doing that research. ASHLEY GLODE: So you guys brought up some good points about there being a lack of data, but also there is some evidence. So what is the current research and evidence on the efficacy of medical cannabis for management of cancer symptoms and cancer pain, specifically? DANIEL BOWLES: So there was a really nice review article that just came out in the BMJ looking at cannabis and cannabinoids, not specific to cancer pain, but including cancer pain. And what they found-- they looked at different preparations from herbal products-- smoked herbal products, oral agents-- cannabinoids, more specifically. They found there is a modest, but a real improvement in pain in patients or research subjects treated with cannabinoids versus those usually typically treated with placebo. In particular, the data are supported in neuropathic pain, I'd say more so than the other pains. I think the data are less compelling with regards to many of the other symptoms that people often use cannabinoids for, such as sleep, anxiety, appetite, things along those lines. ILANA BRAUN: So I'll tell you a little bit about how I think about the evidence base in oncology for cannabis use. So I'll preface this with two points. The first is that, as I mentioned, cannabis products tend not to be one active ingredient, but hundreds of active ingredients-- cannabinoids, phenols, terpenes, they all have bioactivity. And they don't work individually, they work through complicated synergistic and inhibitory interactions that have been termed entourage effects. So I don't think one can easily extrapolate from clinical trials of, say, purified THC, to understand whole-plant cannabis' activity in the body and how it might perform in humans. And then the other point I'll make is that when I think about the types of clinical evidence that we as clinicians hold dearest, it's clinical trials of our agent of interest in our population of interest. So cancer patients using whole-plant full-spectrum cannabis that they would access at a dispensary or grow in their own home. With this in mind, I believe the strongest evidence, randomized double-blind placebo controlled trials of whole-plant cannabis and oncology populations begins to support its utility for chemotherapy-induced nausea and vomiting. So there have been a few studies that have looked at this. But just in 2020, the most recent is a study by Grimison, et al. It was a multicenter randomized double-blind placebo controlled crossover trial comparing cannabis extract. And I think the extract they use was a 1 to 1 THC to CBD ratio versus a placebo in patients with refractory chemotherapy-induced nausea and vomiting. And what they found was that with active drug, there was a complete response in 25% of participants versus only 14% with the placebo. And although a third of participants experienced additional side effects with the active drug-- so remember, this was a crossover trial, so they saw both arms-- 80% preferred cannabis to the placebo medication. So that's clinical trials of cannabis and cancer. But if we expand the base of the pyramid of acceptable evidence to include high-quality clinical trials for health conditions other than cancer and extrapolate back, then I agree fully with Dr. Bowles that there's a growing body of evidence that cannabis may be beneficial in pain management. And there have been many clinical trials done in this arena, and they span myriad pain syndromes, including diabetic neuropathy, post-surgical pain, MS pain, sickle cell pain. And so it does seem like cannabis works for pain management in several other illness models, so we could extrapolate back and hope that it works in cancer pain. And then there is a small body of evidence with nabiximols, which is a pharmaceutical that has a 1 to 1 THC to CBD ratio. And it's a sublingual metered dose spray. And it has been trialed for opioid-resistant cancer pain. And this is not as a single agent, but as an adjuvant to opioids. In early trials, two times as many participants in the active arm as compared to the placebo arm demonstrated a 30% pain reduction. And for the pain specialists who are listening, they will know that is a substantial pain reduction. But then, additional studies fail to meet primary endpoints. I think there were three clinical trials that followed. Nabiximols was found to be safe and effective by some secondary measures, but the FDA opted not to approve nabiximols for cancer pain. So I think there's some suggestion of effect, but there's some smoke, but no fire-- no pun intended. DANIEL BOWLES: I think many of the studies that have been done looking at cannabis-- or cannabinoids-- have been compared to placebo or they've been crossover. And I would say fairly consistently, there is some improvement in pain scores with the cannabis products versus placebo kind of across a wide variety of disease spectrums with regards to pain. I think one of the other questions that a lot of people have asked is, can you decrease people's opiate usage using cannabis? As we know, there's a huge epidemic of opiate misuse in the United States of America right now. And I think many people are looking for ways to decrease opiate usage. There was a nice study done from Minnesota in conjunction with the Minnesota dispensaries-- or state marijuana program-- where some researchers randomized people to starting kind of herbal cannabis products early in their study or three months into their study. So it was kind of a built-in control. And they looked at opiate usage rates, pain scores, quality of life scores, et cetera. What they found is there, again, was some improvement in pain control overall in the cannabis users. However, it did not equate to a decrease in opiate usage. So I think that it's an open question that I think a lot of people want to know the answers to before they start recommending or incorporating cannabis or cannabinoids more widely into their practice. KENT HUTCHISON: It's certainly a complicated issue, in some ways, right? Because the research which is summarized very nicely by both Dr. Braun and Dr. Bowles, it is suggested, but not overwhelming, by any stretch, right? It's not clear-cut. And I think that one of the big issues here we talked about the very beginning is how complicated this cannabis thing is. and Dr. Braun alluded to this also, that there are obviously many different formulations, many potentially active constituents in cannabis. And so what has mostly been studied so far is either synthetic versions of THC or nabiximols, which is probably the closest thing to what some people are using. So I think the jury's still out, for sure. And I think hopefully at some point, what will happen is that some of the products that are actually being used by people-- because most people aren't using nabiximols, most people are not using THC only, hopefully there'll be some trials of the things that people are actually using out there in the real world that will tell us something more about whether it's effective or not. And maybe even more specifically, which constituents-- which parts, together are most effective with respect to pain. DANIEL BOWLES: I think one of the other topics that some of my colleagues have alluded to already is not just cannabis' role in symptom management. I think pain is often what people think of, and people are using it for chemo-induced nausea and vomiting, anxiety, sleep, appetite, but a fair number of patients are also using cannabis or cannabinoids with the hopes that it is going to treat their cancer like a chemotherapy or an immunotherapy may. And oftentimes, patients will point to preclinical studies looking at oftentimes very high doses of THC or CBD that might show tumor cell death or tumor reduction in test tubes. And I spent a fair amount of time-- and I know some of my colleagues spent a fair amount of time-- talking with patients about how it's a big step between cannabis or cannabinoids working to slow cancer growth in a test tube, to working in an animal system, to working in people. ASHLEY GLODE: So what are the most important considerations clinicians should keep in mind before recommending medical cannabis to patients with cancer? DANIEL BOWLES: We should be asking why they want to use cannabinoids. I think just like we might any other medication that people are thinking about trying-- or herbal product that people are thinking about trying-- I think we need to ask why they're interested in using these products. So is it for symptom management? Is it for some of the ancillary side effects of cannabinoids or cannabis? Why are they wanting to use it? And I think trying to incorporate that more than into the medical model, I ask my patients, hey, if you're using this particular product, do you feel like it's doing what you intended it for it to do? If it is and it's legal in your state, great. Do it as you feel fit. If it's not meeting your goals, if it's not helping with the pain, or if it's not helping with the anxiety, or it's not helping with the nausea and vomiting, maybe we should rethink whether we would use it. Just as if I was prescribing more conventional anti-nausea medication and you didn't think it was working, we wouldn't keep using it. So I think that's a really important thing to keep in mind. I think the other thing to know from a safety standpoint is, who else is in the household? We have a psychiatrist on the call with us today. I think there is an ample amount of data that cannabis is not safe for young people. It's not safe for growing brains. And I think we need to make sure, just as we would want people's opiates to be secured, that their cannabinoids and cannabis products are secured as well, from those who do not want to use them. ILANA BRAUN: And the thing I would keep in mind is that in most states, giving patients a medicinal cannabis card is allowing them to access any number of products with different ratios of active ingredients, delivery mechanisms, onset of action, potencies. And if you don't discuss all of these issues with your patients, these are things that they will decide at the dispensary counter, or by discussing with friends and family, or by trial and error. And I think it's really important that we clinicians guide this narrative. ASHLEY GLODE: So what kinds of patients are not good candidates for medical cannabis? DANIEL BOWLES: I would not recommend medical cannabis for people who can't meet some of the criteria we already discussed. So people who can't keep it safe in their households or have concerns about diversion in their own households. Those are people who I think would not be great candidates for medicinal cannabis or cannabinoids. ILANA BRAUN: As the psychiatrist on the call, I would add that I worry for people with a strong history of psychosis, or currently psychotic, or with a strong family history of psychosis. And perhaps those severely immunocompromised, since there is evidence of fungal and mold contamination in some cannabis products. DANIEL BOWLES: The other group of people I discussed this with are patients on immunotherapies. One of the ways that cannabis may be effective in some of the symptoms we discussed is it's an anti-inflammatory agent. One of the ways it could be detrimental for patients on immunotherapies is that it's an anti-inflammatory agent. There is one small study that suggested that patients might have worse responses to immunotherapy who are cannabis users versus those who are not. So that is a conversation I like to have, just so patients feel like they can be informed. I think lastly, cannabis even for people with medical cards, is not free. So there can be a financial burden for people who are using it. So that's something that I'll often bring up with people as well. KENT HUTCHISON: One thing I would add to this would be history of a substance use disorder might also be a consideration here as well. Mainly because you don't know what the person is going to get, and it could be something that lends itself to relapse or encourages a problem. So I would add that to list. ILANA BRAUN: And I would second what Dr. Bowles said about the financial challenges of using cannabis regularly medicinally. It's not something that's covered by insurance, either. So these are out-of-pocket expenses, and they can add up fast, particularly for patients in the oncology space using it for antineoplastic therapy. ASHLEY GLODE: So is there a concern about drug-drug interactions for patients currently undergoing active cancer treatment? DANIEL BOWLES: There are some data that there can be drug-drug interactions with cannabis and certain agents. In particular, cannabidiol, or CBD, is a CYP3A4 inhibitor. And there are a lot of drugs that are metabolized through that particular system. So I think that that's the clinical relevance of those interactions, I think, is sometimes unknown. But that is another topic that I do think we need to make sure we bring up with our patients. ASHLEY GLODE: Thank you. Yeah. So a lot of what we'll do is from a drug interaction perspective, use the FDA-approved products that we have available to run through a drug interaction checker, like Dr. Bowles mentioned. So we'll use dronabinol as the THC-based product and epidiolex as the CBD-based product. There's also some resources, such as natural Medicines Database. And some of the pharmacy programs that we use, you can actually put in marijuana or cannabis as a drug and run drug interaction checks. So there's multiple potential interactions, like he mentioned, through the immune system. But through the cytochrome P450 pathway, cannabis has been shown in some instances to be an inhibitor, sometimes an inducer of certain enzymes, as well as a substrate. So it's really important to work with your pharmacy colleagues to run through different potential interactions that may be present. ILANA BRAUN: I'll just add one thing, just in case that's helpful. I mentioned earlier in the episode that I had a patient who used cannabis as an antineoplastic drug, and targeted very high doses and developed a terrible nausea and vomiting. And when she stopped, so did the nausea and vomiting, even though her chemotherapeutic continued. And I, to this day, don't know if that was a cyclic nausea and vomiting syndrome, which has been known to plague some heavy cannabis users, or whether drug-drug interactions led to her high-dose cannabis triggering high blood concentrations of her cancer-directed therapy at the time. And so I think that drug-drug interactions do need to be carefully weighed. ASHLEY GLODE: So wrapping up, has the medical community stance on medical marijuana shifted in recent years with legalization in many states? ILANA BRAUN: I don't think we know the answer to this, about how sentiment has shifted because there aren't longitudinal studies that I know of examining this question. But we need some. And one could imagine that as medicinal cannabis becomes are commonplace, providers are increasingly confronted with questions about how to guide care and the desire for high-quality clinical trials and in-depth cannabis therapeutics trainings increases-- and as one piece of evidence for this, at the end of 2020 the National Cancer Institute held a first-in-kind four-day conference at the intersection of cannabis and cancer. And so I'm hopeful that grant opportunities will follow from that. DANIEL BOWLES: I think overall there has been more willingness to discuss cannabis in the context of patient care in the last decade. A couple of ways that I see this is I much more frequently see cannabis use described not necessarily in the drug history, or in the social history, but in the medical history, or in their medications, if they're using it for medical or therapeutic purposes. I think the other place that I've noticed cannabis usage become a bit more mainstream is in the clinical trial setting-- not in clinical trials of cannabis, but one of the things that many of us do is clinical trials of new drugs. And very frequently, 10 years ago we ran into trouble trying to get our patients who were using cannabis products for cancer symptom control onto these clinical trials because of potential drug-drug interactions, or just the fear of the unknown. And I feel like we run into that less commonly now. KENT HUTCHISON: I think it's also worth pointing out that there have been more and more podcasts like this one, right? So to the credit of this organization, I think we are seeing some change. I just wanted to highlight that. And I compliment everyone here for putting us together and putting it out there. ASHLEY GLODE: All right. Well, thank you. That is all we have for today. And thank you very much Drs. Braun, Bowles, and Hutchison for a delightful conversation. Thank you so much to all the listeners tuning into this episode of the ASCO Education Podcast. [MUSIC PLAYING]   SPEAKER: Thank you for listening to this week's episode to make us part of your weekly routine, click Subscribe. Let us know what you think by leaving a review. For more information, visit elearning.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Cultura em Pauta #119, 21 de outubro de 2021(00:17) Estreia de nova versão Duna nos cinemas(01:10) Turnê de Cristiane Couto em diversas cidades de Goiás(02:20) Ateliê do Gesto convida para estreia do espetáculo "dança boba" em meio virtual(03:36) Programa de Quinta com Nila Branco e Raimundo Alves(04:15) Oásis, Nila Branco◽ Criação e apresentação: Mazé Alves◽ Redação e edição de texto: Leonardo Mendonça | Mazé Alves◽ Design gráfico: Laura Jorge◽ Edição: Eduardo Farias◽ Publicação: Givaldo Corcinio◽ Direção Artística: Vanderley Santana◽ Coordenação do Departamento de Conteúdo TV Brasil Central: Mazé Alves◽ Produção: TV Brasil Central – RBC FMRealização: Agência Brasil Central - Goiás#NilaBranco #RaimundoAlves #espetáculo #musica #dança #programadequinta #PdQ #cinema #AteliedoGesto #CristianeCouto #turne

La rencontre Nadeau-Robitaille avec Rémi Nadeau, chef de bureau parlementaire à l'Assemblée nationale pour le Journal et le Journal : l'analyse sportive de la PDQ avec l'orgue! L'anguille de la journée: Jonatan Julien! La prestation théâtrale: Catherine Dorion, qui se demande pourquoi le 3e lien n'a pas été évoqué dans un discours dans lequel le PM projetait le Québec dans l'avenir. Le tir à blanc : Isabelle Melançon a eu peu de succès contre Benoit Charette sur la question climatique/Dominique Anglade qui relevait l'absence du mot «pénurie» de main-d'oeuvre. Le tir à côté de la cible: Joël Arseneau et la place du Québec au sein du Canada. Entrevue avec Éric Bédard, historien, professeur à la Télé-Université, auteur de «LE QUÉBEC Tournants d'une histoire nationale» qui paraît ces jours-ci au Septentrion : Il a beaucoup été question de la décision du Club de Hockey Canadiens d'affirmer, au début des matchs de Hockey au Centre Bell, qu'on se trouvait sur un territoire traditionnel mohawk.On doit aussi transmettre un sentiment de fierté, de citoyenneté partagée, puis, pour y arriver, pour y arriver, on va remplacer le cours d'éthique et culture religieuse par un cours axé sur la culture et la citoyenneté québécoise. Retour sur les mots et analyse d'Éric Bédard.  Une production QUB radio  Octobre 2021 Pour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

La rencontre Nadeau-Robitaille avec Rémi Nadeau, chef de bureau parlementaire à l'Assemblée nationale pour le Journal et le Journal : l'analyse sportive de la PDQ avec l'orgue! L'anguille de la journée: Jonatan Julien! La prestation théâtrale: Catherine Dorion, qui se demande pourquoi le 3e lien n'a pas été évoqué dans un discours dans lequel le PM projetait le Québec dans l'avenir. Le tir à blanc : Isabelle Melançon a eu peu de succès contre Benoit Charette sur la question climatique/Dominique Anglade qui relevait l'absence du mot «pénurie» de main-d'oeuvre. Le tir à côté de la cible: Joël Arseneau et la place du Québec au sein du Canada. Pour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

No Babble again this week due to a last minute production cock-up, so it's re-run time again. As the impacts of climate change are very much top of everyone's mind right now, we thought you might appreciate our chat about all things 'how buggered could the climate get anyway', with Mark Lynas (original broadcast: April 2020). Disclaimer: climate science moves fast, and there's dicussion in here about the potential for the gulf stream to slow down, which the news recently reported scientists are increasingly worried may be happening. Back in early 2020 Mark wasn't that worried about it. Bear in mind that that was then, when you listen to that bit. If the global pandemic is leaving you wanting more on the existential angst front, try dipping into chapter 6 of journalist and former activist Mark Lynas' new book, 'Our Final Warning', where you'll read that at six degrees of global heating "a wave of mass extinctions threatens life on earth". Theeeeeeere we go, that's the good stuff.The book, to an extent an updated version of 2007's groundbreaking 'Six Degrees', describes the most recent scientific understanding of what we can expect if carbon emissions don't fall rapidly and temperatures continue to rise. Or, in other words, the civilisation-ending shitstorm that's in the post if humanity doesn't get its act together PDQ.We chat to Mark about what's changed - good and bad - in the twelve years between the two books, what Covid-19 might mean for global emissions, and why, despite it all, he retains a sense of optimism.Sustainababble is your friendly environment podcast, out weekly. Theme music by the legendary Dicky Moore – @dickymoo. Sustainababble logo by the splendid Arthur Stovell. Ecoguff read out by Arabella. Love the babble? Bung us a few pennies at www.patreon.com/sustainababble. MERCH: sustainababble.teemill.com Available on iTunes, Spotify, Acast & all those types of things, or at sustainababble.fish. Visit us at @thebabblewagon and at Facebook.com/sustainababble. Email us at hello@sustainababble.fish.

Join Dr. Lycka for this fascinating interview with Kelly Falardeau, a former patient, now an author, speaker and mentor.  Kelly discusses the essential ingredient of building your profile; writing a book.   Your book will not only act as a calling card but an impressive CV and just might be your pass to a new career in coaching, training or speaking.  Kelly's helpful method will put you on the road to writing PDQ!   Guest Bio:   Kelly is a burn survivor since the age of 2 on 75% of her body. She found a way to go from near death to SUCCESS, from the ugly scar-faced girl to the TEDx stage, not once but twice. A documentary about her life story, called STILL BEAUTIFUL launched on TV plus Goalcast launched a video that has almost 10 million views. Now she is a full-time Best-Selling Author Strategist, coaching people to become best selling authors. On Christmas day Global tv announced Kelly as one of the Most Inspirational People of 2020.    WEBSITE:  www.7StepsAuthor.com  or www.KellyFalardeau.com FACEBOOK:https://www.facebook.com/kellywoodhousefalardeau CLUBHOUSE:@kellyfalardeau or @authorclub YOUTUBE: https://youtube.com/c/KellyFalardeau LINKEDIN: https://www.linkedin.com/in/kellyfalardeau/ INSTAGRAM: HTTPS://www.instagram.com/kellyf.7stepsauthor TWITTER: https://www.twitter.com/kellyfalardeau PINTEREST: https://www.pinterest.ca/KellyBestsellerstrategist   Thanks for listening to the show! It means so much to us that you listened to our podcast! If you would like to continue the conversation, please email me at allen@drallenlycka.com or visit our Facebook page at http://www.facebook.com/drallenlycka. We would love to have you join us there, and welcome your messages. We check our Messenger often.  As a big thank you for listening to our podcast, we'd like to offer you a free copy of Dr. Lycka's bestselling book the show is built on “The Secrets to Living A Fantastic Life.” Get your free copy by clicking here: https://secretsbook.now.site/home We are building a community of like-minded people in the personal development/self-help/professional development industries, and are always looking for wonderful guests for our show. If you have any recommendations, please email us!   Dr. Allen Lycka's Social Media Links Facebook: http://www.facebook.com/drallenlycka Instagram:  https://www.instagram.com/dr_allen_lycka/ Twitter:  https://www.twitter.com/drallenlycka LinkedIn:  https://www.linkedin.com/in/allenlycka YouTube:  https://www.YouTube.com/c/drallenlycka   Subscribe to the show We would be honored to have you subscribe to the show – you can subscribe on the podcast app on your mobile device.   Leave a review We appreciate your feedback, as every little bit helps us produce even better shows. We want to bring value to your day, and have you join us time and again.  Ratings and reviews from our listeners not only help us improve, but also help others find us in their podcast app. If you have a minute, an honest review on iTunes or your favorite app goes a long way! Thank you!

Brian Lanier, CFO of PDQ.COM. joins me to discuss frameworks and thought processes around the pricing of SaaS products. Brian recently joined PDQ.com and we speak briefly about his top priorities as a new CFO. Next, we dive deep and discuss the ways he has approached SaaS product pricing including: constructing a pricing model, resolving pricing differences, Identifying when pricing needs to be adjusted.

Today Business Property Pro Mike Gioioso heads to the "City of Brotherly Love" for a Retail Market update from Commercial Real Estate thought leader, Rob Samtmann. Rob Samtmann has been active in the commercial real estate industry as a Tenant Representation Broker or Landlord Representation Broker in the Philadelphia Metropolitan Area since 1995. At present, he is now a managing Principal with Equity Retail Brokers - www.equityretailbrokers.com In Rob's career at Equity Retail Brokers he has been fortunate to work with retailers including ShopRite Supermarkets, Shoe Carnival, Gander Mountain, BJ's Wholesale Club, Babies R Us/Toys R Us, Lowe's Home Improvement, Starbucks, Friday's, Party City, Sleep Number Beds, Vitamin Shoppe, Pep Boys, Firestone, FedEx, Pet Supplies Plus, Quaker Steak & Lube, Wendy's, PDQ, Wells Fargo, Travinia, Ten Thousand Villages, Thirsty Lion, Rite Aid, Alton Lane, Capriotti's, Empire Beauty, Arby's, PNC Bank, Verizon Wireless, Sleep Number, Lou Lou Boutique, Pet Valu, Primrose Schools, Red Robin, Rumble Boxing, Applebee's, Lime Fresh, Pancheros, Outback Steakhouse, Ruby Tuesday, TGI Friday's, STS Tire, Banfield Pet Hospital, Blue Pearl Pet Hospital, C2 Education, Oportun, Rumble Boxing, Noah's, and Kindercare. Rob and Mike frequently collaborate through their participation in the Retail Brokers Network (RBN) - www.retailbrokersnetwork.com , an association of 60+ Independent Commercial Real Estate firms throughout the United States and Canada. In today's episode we chat about what's on trend in the retail drive through and pad universe, what Rob witnesses working in the current Pandemic-hobbled state of Retail, and we collect some beginner tips on Rob's favorite tech toy.... his DJI Drone! For more Business and Commercial Real Estate insider insight, please subscribe! or follow me on social @businesspropertypro. www.businesspropertypro.com Business Property Pro is the blog of Mike Gioioso, Vice-President of Brokerage at MacKenzie Commercial Real Estate Services. Mike is committed to serving clients in hopes of achieving their customized goals, whether or not those goals require brokerage assistance. IT'S ALL ABOUT FULL SERVICE MacKenzie's seven firms provide clients a competitive, full-service platform of offerings in leasing, sales, investment sales, tenant and landlord advisory services, corporate and business consulting, development, general construction, property and asset management, multifamily management, debt and equity capital placement, and GIS/data analytics. With more than 225 employees, MacKenzie is one of the largest, non-affiliated full-service commercial real estate firms in the Mid-Atlantic. Together, our associates prove time and again why we are the company you keep. Let's chat : hello@businesspropertypro.com

Show Notes In this episode of The Sailing Rode Podcast we talk with Mike and Rebecca Sweeney about their transition from a catamaran to a monohull. Interview Check out their cruising blog with over 2000 posts!  http://www.zerotocruising.com/ Buy their previous cruising PDQ 32 catamaran - ZTC is for Sale! http://www.zerotocruising.com/pdq-32-for-sale/ Check out Rebecca's boat workout site:  StrengthPlus!  http://www.strengthplus.ca/   Kettlebell workout on a boatGrab your kettlebell and try these exercises for a full-body workout! Last Minute Christmas Gifts for Sailors Magazines! Cruising Outpost - a great magazine about the cruising lifestyle Good Ole Boat - great magazine out loving slightly used good ole boats Wooden Boat - A beautiful magazine that will make you fall in love with wooden boats Practical Sailor - The consumer guide for sailing Attainable Adventure Cruising - becoming the ultimate cruising guide and the Adventure 40 is a cool boat design to check out Sailing Stories Sailing is a Sport and Deserves your Respect by Andrew Mather, The Stanford Daily French cup skipper nearly loses foot in sailing accident Please help us Support Podcast We need your help to spread the word about the Podcast.  Please share the podcast with your sailing friends and ask them to subscribe on iTunes or Stitcher.  You can send them these links: iPhone iTunes link: https://itunes.apple.com/us/podcast/the-sailing-rode/id1033604152 Android Stitcher link: http://www.stitcher.com/podcast/the-sailing-rode It also helps when you share the podcast links on social media and sailing forums. Patreon If you enjoy the podcast, please consider supporting us through our Patreon site.  Your support helps cover the cost to produce the podcast and provides resources to help us deliver new kinds of content.  Check it out at this link: https://www.patreon.com/TheSailingRode How it works:  Patreon is designed for content creators, like us.  We make podcasts and videos about sailing and you can help support our creations by signing up for a small fee per podcast.  You can set a maximum monthly amount so if we release a lot of podcasts in one month, you still only pay your maximum amount.  It is kind of like giving us a tip or buying us a drink after a good show. Please use our Amazon Affiliate link for anything you buy on Amazon or look at over 90 items we have in our TSR Amazon store.  We use all the items on our boat and include notes of why we like them.  We also added over 40 great sailing and cruising books we recommend.  You pay the same low Amazon price and we get a small commission. Please like or follow us on Youtube, Facebook, Twitter, and Instagram  We will follow you too! Send us your feedback on the show and any show topic ideas to Crew@TheSailingRode.com We wish you fair winds and hope to see you on the water soon. Thanks for listening!   –  Steve & Brandy The Sailing Rode Sailing Podcast

Although this episode is entitled “innovation in insurance” – there is much food for thought of far wider applicability. Fintech narratives often slip into “disrupting banking” – whereas this is just a part of Financial Services – insurance is another vast part. There is another narrative that assumes innovation is the preserve of the “t-shirts” not the “suits” – whereas in practice in the sector as a whole there has been massive (excess even?) innovation in recent decades. Furthermore there are some FS incumbents who were born out of innovation and still live and breathe it. Against this backdrop I am delighted to have on the show John Shaw Head of R&D and Innovation at the Direct Line Group.  John is a great person to talk about innovation in FS as he has had gigs in a rare breadth of FS-sectors – consumer, private, and commercial banking before moving into insurance. John’s very B2C marketing background is also a great counterbalance to LFP005 which was much more B2B focused.  We start the show by discussing how we learned Marketing and Sales in the City – for John this was “meat and potatoes”. For me (coming from “ultra-B2B” City origins) I kinda had to work it out myself over time as the old imperial vibe of the last thing one wants to be was “in trade” (commercial? shudder!) pervaded much of merchant banking. This B2C vs B2B division is a huge fault line in the Fintech scene which I have never seen alluded to.  In essence if your business needs thousands or millions of transactions then there is one philosophy of how to address the marketing and selling functions [and this is the default “tech” vibe imported from the Valley].  Vice versa (and this is where techs can run into problems having de facto absorbed a tech sic B2C vibe) if a dozen deals a year is a lot for you – you need the B2B approach we discussed in the prior episode. In getting feedback from chums who know the insurance market, everyone singled out Direct Line as being “real class”.  In a way it was founded innovatively and continues in that vein.  As is evidenced by this episode incumbents who embrace innovation can have a significant advantage in employing the likes of John to run an innovation team and get a very strategic grasp on their marketplace. John’s view is that corporates rarely lack for good ideas but more often lack a means of trying and trialling and tweaking them to get success before then going on to industrialise them. We didnt capture this point on mic but he (like I) is very much against the whole idea (all too commonly seen in London incubators/accelerators) that innovation equals bean bags, ping-pong tables etc.  Again if one subtracts the “valley vibe” there is no need to be teenage or childish to be innovative.  Equally he is averse to the idea of “blue sky thinking” focusing more on delivering. John lays out the strategic challenges for insurance coming from changing consumer behaviours in terms of key pillars of: the Internet of Things Quantified Self (more accurate data => more accurate pricing) Telematics (ditto but data on devices (eg cars)) P2P/community insurance – eg: Bought by Many (social insurance and one of the best examples of an innovative insurance fintech) and a cracking tale about the “very French” “Mutuelles des Fraudeurs”! Ownership to usership the “End of Inefficiency” I was very impressed by the grasp of the strategic threats and opportunities and mention that I have never seen (yet anyway) such a grasp of strategic innovation in banks [in LFP002 Warren Bond referred to the key roles of innovation departments in banks as currently facilitating the introduction of innovation into banks – not to originating it]. It hadn’t struck me before but the Insurance sector had wake-up calls ahead of the banking sector.  This may be why relatively speaking it has less “really low hanging fruit” (unlike banks around FX and payments).  The first wake up call was the move to online buying and the second was the advent of price comparison websites (which are looking to move more into value comparison (ie including quality as well as price)).  If insurers were lagging and dragging feet before these, then once the business started walking out of the door they had to respond PDQ. If you like this or other shows please subscribe on iTunes, by App or by email at the top of the column on the right to be informed of new episodes.  And please help spread the word using all those social media buttons below or even the old-fashioned method of just telling your chums